Clinical trial

Strength Training Response of Muscle in GLP-1 Users

Recruiting now · Not applicable · 1 countries · Registry ID NCT07104539

Recruiting nowNot applicableInterventional

What this study is about

GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age50 Years to Not listed

SexAll

Healthy volunteersAccepted

ConditionMuscle Mass

Full registry criteria

Inclusion Criteria: * Age, 50y+ * Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less * Weight \<300 lb * Pass a health and exercise readiness screening Exclusion Criteria: * Age \<50 * Weight \>300 lb * Osteoporosis * Active metabolic, neoplastic, or cardiovascular disease * Unable or unwilling to provide consent

Treatments and study arms

Strength Training

Behavioral

Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.

Wait first, then strength training

Other

Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.

Primary outcomes

Muscle mass by d3-creatine dilutionWater containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks.

Participants will collect a urine sample prior to be provided a creatine capsule containing 30 milligrams of a naturally-occurring creatine isotope. A glass of water will be provided to wash it down. Participants will be asked to return \~3 days later to provide another urine sample. Urine samples will be analyzed at an off-site laboratory to determine changes in d3-creatine excretion before and after the 14-week strength training intervention.

Balance testing - Percentage of failed recoveries2-hour testing session in lab at baseline and 14 weeks.

Participants will stand on the treadmill with the belt stationary. The belt will then suddenly change to a speed specified by the investigator, and the participant will attempt to step to maintain their balance and establish a stable gait. In addition to the treadmill itself, this system includes an integrated fall arrest harness that is anchored to an overhead gantry that is fixed to the treadmill. This harness prevents any body part but the feet from impacting the treadmill in the event that the participant is unable to maintain their balance after a sudden change in speed.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Virginia Tech🇺🇸 Blacksburg, Virginia, United States

Open map